When was Menten founded?

Menten was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Menten located?

Menten is headquartered in San Francisco, United States.

Who is the current CEO of Menten?

Hans Melo of Menten. They have also founded 1 company.

How many employees does Menten have?

As of Aug 31, 2026, the latest employee count at Menten is 19.

Is Menten a funded company?

Menten is a funded company, having raised a total of $4.15M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 18, 2020.

How much is Menten worth?

The latest valuation of Menten is $***** as of Mar 18, 2020. This marks a decline of 1% from its peak valuation of $2.14M in Mar, 2020. This marks a decline of 1% from its peak valuation of $2.14M in Mar, 2020.

When was the latest funding round of Menten?

Menten's latest funding was a $***** Seed round on Jun 30, 2020, with participation from 2 investors. Its primary sector is Generative AI. In United States, the Generative AI sector has seen $255B in funding in 2026 to date.

Where does Menten rank among its competitors?

Menten ranks 18th amongst 185 active competitors, of which 52 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Aureka Biotechnologies, which secured $100M in Aug, 2026.

Who are the top competitors of Menten?

Menten's top competitors include Biognosys, Peptris and Talus. Among them, Aureka Biotechnologies secured the most recent funding round in August, 2026.

Menten - 2026 Company Profile, Team, Funding & Competitors

Menten is a seed company based in San Francisco (United States), founded in 2018 by Vikram Mulligan and Hans Melo. It operates as a Developer of peptides using AI technology. Menten has raised $4.15M in funding from investors like Y Combinator, Khosla Ventures and Uncork Capital, with a current valuation of $*****. The company has 185 active competitors, including 52 funded and 12 that have exited. Its top competitors include companies like Biognosys, Peptris and Talus.

Company Details

Menten AI is a developer of a platform for protein designing. The platform uses machine learning and quantum computing to design proteins based on requirements such as protein therapeutics and biocatalysis. The services offered by the company are rational peptide design and enzyme optimization.

Website: menten.ai
Social
Email ID: *****@menten.ai

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Seed

Total Funding

$4.15M in 2 rounds

Latest Funding Round

Seed, Jun 30, 2020, $*****

Post Money Valuation

$***** as on Mar 18, 2020

Investors

Y Combinator & 8 more

Ranked

18^th among 185 active competitors

Employee Count

19 as on Aug 31, 2026

Similar Companies

OpenEvidence & 3047 more

View Menten's full profile

Menten has raised a total funding of $4.15M over 2 rounds. Its first funding round was on Mar 18, 2020. Its latest funding round was a Seed round on Jun 30, 2020 for $*****. 2 investors participated in its latest round. Menten has 9 institutional investors.

Here is the list of recent funding rounds of Menten:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 30, 2020	1536902	Seed	7520536	4758129	6361419	3897381
Mar 18, 2020	4427309	Seed	6988880	1369979	Y Combinator	6140328

Access funding benchmarks and valuations. Sign up today!

View details of Menten's funding rounds and investors

The founders of Menten are Vikram Mulligan and Hans Melo. Hans Melo is the CEO of Menten.

Here are the details of Menten's key team members:

Vikram Mulligan: Co-Founder & CTO of Menten.
Contact Info: 1 email address
Hans Melo: Co-Founder & CEO of Menten.
Contact Info: 1 email address

View details of Menten's Founder profiles and Board Members

Menten's employee count trend

Menten has 19 employees as of Aug 26. Here is Menten's employee count trend over the years:

Uncover Menten's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Menten include Biognosys, Peptris and Talus. Here is the list of Top 10 competitors of Menten, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biognosys 2008, Schlieren (Switzerland), Acquired	Provider of proteomics service	$9.13M	Syngenta Group, Zurcher Kantonalbank & 6 others	63/100
2nd	Peptris 2019, Bengaluru (India), Series A	Provider of AI-based proteomic data analysis software for drug discovery	$9.17M	Speciale Invest, Indian Angel Network Fund ... & 46 others	61/100
3rd	Talus 2020, Seattle (United States), Seed	Provider of drug discovery platform for gene regulators	$19.8M	Fifty Years, Y Combinator & 11 others	60/100
4th	Unnatural Products 2016, Santa Cruz (United States), Series B	Developer of computational biology techniques platform to engineer peptides for undruggable targets	$83M	Artis Ventures, Merck Global Health Innovation Fund ... & 17 others	57/100
5th	BridGene Biosciences 2018, Sunnyvale (United States), Series B	Developer of small-molecule drugs for the treatment of cancer	$78.5M	Deyi Capital, Lapam Capital & 8 others	57/100
6th	Aureka Biotechnologies 2023, Laguna Hills (United States), Series B	Biotech company digitizing therapeutic discovery to manage human health	$200M	5Y Capital, Qiming Venture Partners & 6 others	55/100
7th	ProteinSimple 2004, San Jose (United States), Acquired	Provider tools to help researchers with protein analysis	$94.3M	Lansing Brown Investments, Royal Bank of Canada ... & 10 others	54/100
8th	Avenue Biosciences 2023, Palo Alto (United States), Seed	Biotechnology company that employs protein engineering solutions	$9.94M	Balnord, Voima Ventures & 4 others	54/100
9th	Cyrus Biotechnology 2014, Seattle (United States), Series B	Developer of cloud-based protein-modelling software for drug discovery	$32M	Trinity Ventures, Agent Capital & 11 others	53/100
10th	HeliXon 2009, China, Series A	Developer of an integrated platform for protein therapeutic discovery and optimization	$74.7M	5Y Capital, Hillhouse & 4 others	51/100
18th	Menten 2018, San Francisco (United States), Seed	Developer of peptides using AI technology	$4.15M	Uncork Capital, Khosla Ventures & 7 others	43/100